Selected research
Industry Research
Rasagiline Mesylate Tablets Industry Research Report 2026
Market perspective
The global Rasagiline Mesylate Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Rasagiline Mesylate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Rasagiline Mesylate Tablets is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Rasagiline Mesylate Tablets is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Rasagiline Mesylate Tablets include Teva Pharmaceutical, Sun Pharmaceutical, Sandoz, Mylan, Takeda Pharmaceutical, Taj Pharma, Orchid Pharma, Natco Pharma and Lundbeck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Rasagiline Mesylate Tablets market in terms of revenue (US$ million) and, where applicable, sales volume (W Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rasagiline Mesylate Tablets Market by Company
Teva Pharmaceutical
Sun Pharmaceutical
Sandoz
Mylan
Takeda Pharmaceutical
Taj Pharma
Orchid Pharma
Natco Pharma
Lundbeck
Intas Pharmaceuticals
Apotex
Alkem Laboratories
Ajanta Pharma
Rasagiline Mesylate Tablets Segment by Type
0.5 mg/Pcs
1 mg/Pcs
Rasagiline Mesylate Tablets Segment by Application
40-65 Years Old
Under 40 Years Old
Above 65 Years Old
Rasagiline Mesylate Tablets Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rasagiline Mesylate Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rasagiline Mesylate Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rasagiline Mesylate Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rasagiline Mesylate Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rasagiline Mesylate Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rasagiline Mesylate Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.5 mg/Pcs
- 1 mg/Pcs
Applications
- 40-65 Years Old
- Under 40 Years Old
- Above 65 Years Old
Companies covered
- Teva Pharmaceutical
- Sun Pharmaceutical
- Sandoz
- Mylan
- Takeda Pharmaceutical
- Taj Pharma
- Orchid Pharma
- Natco Pharma
- Lundbeck
- Intas Pharmaceuticals
- Apotex
- Alkem Laboratories
- Ajanta Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Rasagiline Mesylate Tablets Market Size (2021-2032)
- 2.2.2 Global Rasagiline Mesylate Tablets Sales (2021-2032)
- 2.2.3 Global Rasagiline Mesylate Tablets Market Average Price (2021-2032)
- 2.3 Rasagiline Mesylate Tablets by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.5 mg/Pcs
- 2.3.3 1 mg/Pcs
- 2.4 Rasagiline Mesylate Tablets by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 40-65 Years Old
- 2.4.3 Under 40 Years Old
- 2.4.4 Above 65 Years Old
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Rasagiline Mesylate Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Rasagiline Mesylate Tablets Sales (W Pcs) of Manufacturers (2021-2026)
- 3.3 Global Rasagiline Mesylate Tablets Revenue of Manufacturers (2021-2026)
- 3.4 Global Rasagiline Mesylate Tablets Average Price by Manufacturers (2021-2026)
- 3.5 Global Rasagiline Mesylate Tablets Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Rasagiline Mesylate Tablets, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Rasagiline Mesylate Tablets, Product Type & Application
- 3.8 Global Manufacturers of Rasagiline Mesylate Tablets, Established Date
- 3.9 Global Rasagiline Mesylate Tablets Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Rasagiline Mesylate Tablets Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Rasagiline Mesylate Tablets Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 Sandoz
- 4.3.1 Sandoz Company Information
- 4.3.2 Sandoz Business Overview
- 4.3.3 Sandoz Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sandoz Rasagiline Mesylate Tablets Product Portfolio
- 4.3.5 Sandoz Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Rasagiline Mesylate Tablets Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Takeda Pharmaceutical
- 4.5.1 Takeda Pharmaceutical Company Information
- 4.5.2 Takeda Pharmaceutical Business Overview
- 4.5.3 Takeda Pharmaceutical Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Takeda Pharmaceutical Rasagiline Mesylate Tablets Product Portfolio
- 4.5.5 Takeda Pharmaceutical Recent Developments
- 4.6 Taj Pharma
- 4.6.1 Taj Pharma Company Information
- 4.6.2 Taj Pharma Business Overview
- 4.6.3 Taj Pharma Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Taj Pharma Rasagiline Mesylate Tablets Product Portfolio
- 4.6.5 Taj Pharma Recent Developments
- 4.7 Orchid Pharma
- 4.7.1 Orchid Pharma Company Information
- 4.7.2 Orchid Pharma Business Overview
- 4.7.3 Orchid Pharma Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Orchid Pharma Rasagiline Mesylate Tablets Product Portfolio
- 4.7.5 Orchid Pharma Recent Developments
- 4.8 Natco Pharma
- 4.8.1 Natco Pharma Company Information
- 4.8.2 Natco Pharma Business Overview
- 4.8.3 Natco Pharma Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Natco Pharma Rasagiline Mesylate Tablets Product Portfolio
- 4.8.5 Natco Pharma Recent Developments
- 4.9 Lundbeck
- 4.9.1 Lundbeck Company Information
- 4.9.2 Lundbeck Business Overview
- 4.9.3 Lundbeck Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Lundbeck Rasagiline Mesylate Tablets Product Portfolio
- 4.9.5 Lundbeck Recent Developments
- 4.10 Intas Pharmaceuticals
- 4.10.1 Intas Pharmaceuticals Company Information
- 4.10.2 Intas Pharmaceuticals Business Overview
- 4.10.3 Intas Pharmaceuticals Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Intas Pharmaceuticals Rasagiline Mesylate Tablets Product Portfolio
- 4.10.5 Intas Pharmaceuticals Recent Developments
- 4.11 Apotex
- 4.11.1 Apotex Company Information
- 4.11.2 Apotex Business Overview
- 4.11.3 Apotex Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Apotex Rasagiline Mesylate Tablets Product Portfolio
- 4.11.5 Apotex Recent Developments
- 4.12 Alkem Laboratories
- 4.12.1 Alkem Laboratories Company Information
- 4.12.2 Alkem Laboratories Business Overview
- 4.12.3 Alkem Laboratories Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Alkem Laboratories Rasagiline Mesylate Tablets Product Portfolio
- 4.12.5 Alkem Laboratories Recent Developments
- 4.13 Ajanta Pharma
- 4.13.1 Ajanta Pharma Company Information
- 4.13.2 Ajanta Pharma Business Overview
- 4.13.3 Ajanta Pharma Rasagiline Mesylate Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ajanta Pharma Rasagiline Mesylate Tablets Product Portfolio
- 4.13.5 Ajanta Pharma Recent Developments
5 Global Rasagiline Mesylate Tablets Market Scenario by Region
- 5.1 Global Rasagiline Mesylate Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Rasagiline Mesylate Tablets Sales by Region: 2021-2032
- 5.2.1 Global Rasagiline Mesylate Tablets Sales by Region: 2021-2026
- 5.2.2 Global Rasagiline Mesylate Tablets Sales by Region: 2027-2032
- 5.3 Global Rasagiline Mesylate Tablets Revenue by Region: 2021-2032
- 5.3.1 Global Rasagiline Mesylate Tablets Revenue by Region: 2021-2026
- 5.3.2 Global Rasagiline Mesylate Tablets Revenue by Region: 2027-2032
- 5.4 North America Rasagiline Mesylate Tablets Market Facts & Figures by Country
- 5.4.1 North America Rasagiline Mesylate Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Rasagiline Mesylate Tablets Sales by Country (2021-2032)
- 5.4.3 North America Rasagiline Mesylate Tablets Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Rasagiline Mesylate Tablets Market Facts & Figures by Country
- 5.5.1 Europe Rasagiline Mesylate Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Rasagiline Mesylate Tablets Sales by Country (2021-2032)
- 5.5.3 Europe Rasagiline Mesylate Tablets Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Rasagiline Mesylate Tablets Market Facts & Figures by Country
- 5.6.1 Asia Pacific Rasagiline Mesylate Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Rasagiline Mesylate Tablets Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Rasagiline Mesylate Tablets Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Rasagiline Mesylate Tablets Market Facts & Figures by Country
- 5.7.1 South America Rasagiline Mesylate Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Rasagiline Mesylate Tablets Sales by Country (2021-2032)
- 5.7.3 South America Rasagiline Mesylate Tablets Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Rasagiline Mesylate Tablets Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Rasagiline Mesylate Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Rasagiline Mesylate Tablets Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Rasagiline Mesylate Tablets Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Rasagiline Mesylate Tablets Sales by Type (2021-2032)
- 6.1.1 Global Rasagiline Mesylate Tablets Sales by Type (2021-2032) & (W Pcs)
- 6.1.2 Global Rasagiline Mesylate Tablets Sales Market Share by Type (2021-2032)
- 6.2 Global Rasagiline Mesylate Tablets Revenue by Type (2021-2032)
- 6.2.1 Global Rasagiline Mesylate Tablets Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Rasagiline Mesylate Tablets Revenue Market Share by Type (2021-2032)
- 6.3 Global Rasagiline Mesylate Tablets Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Rasagiline Mesylate Tablets Sales by Application (2021-2032)
- 7.1.1 Global Rasagiline Mesylate Tablets Sales by Application (2021-2032) & (W Pcs)
- 7.1.2 Global Rasagiline Mesylate Tablets Sales Market Share by Application (2021-2032)
- 7.2 Global Rasagiline Mesylate Tablets Revenue by Application (2021-2032)
- 7.2.1 Global Rasagiline Mesylate Tablets Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Rasagiline Mesylate Tablets Revenue Market Share by Application (2021-2032)
- 7.3 Global Rasagiline Mesylate Tablets Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Rasagiline Mesylate Tablets Value Chain Analysis
- 8.1.1 Rasagiline Mesylate Tablets Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Rasagiline Mesylate Tablets Production Mode & Process
- 8.2 Rasagiline Mesylate Tablets Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Rasagiline Mesylate Tablets Distributors
- 8.2.3 Rasagiline Mesylate Tablets Customers
9 Global Rasagiline Mesylate Tablets Analyzing Market Dynamics
- 9.1 Rasagiline Mesylate Tablets Industry Trends
- 9.2 Rasagiline Mesylate Tablets Industry Drivers
- 9.3 Rasagiline Mesylate Tablets Industry Opportunities and Challenges
- 9.4 Rasagiline Mesylate Tablets Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst